Luca Benatti - 23 Oct 2024 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role: Director
Signature: /s/ Brendan Hannah as attorney-in-fact for Luca Benatti
Issuer symbol: QNCX
Transactions as of: 23 Oct 2024
Net transactions value: $0
Form type: 4
Filing time: 29 Dec 2025, 17:34:30 UTC
Previous filing: 07 Jun 2024
Next filing: 06 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Benatti Luca	Director	C/O QUINCE THERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 273, SOUTH SAN FRANCISCO	/s/ Brendan Hannah as attorney-in-fact for Luca Benatti	29 Dec 2025	0001613842

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	QNCX	Common Stock	Other		+8,918	+11%		89,179	23 Oct 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	In connection with the Stock Purchase Agreement between the Issuer and EryDel Italy Inc.announced in the Issuer's 8-k filed with the Securities and Exchange Commission on July 24, 2023 (the "Acquisition"), 10% of the shares of common stock of the Issuer issued to the Reporting Person in connection with the Acquisition were held back for one (1) year following closing and released to the Reporting Person on October 23, 2024.

Content

In connection with the Stock Purchase Agreement between the Issuer and EryDel Italy Inc.announced in the Issuer's 8-k filed with the Securities and Exchange Commission on July 24, 2023 (the "Acquisition"), 10% of the shares of common stock of the Issuer issued to the Reporting Person in connection with the Acquisition were held back for one (1) year following closing and released to the Reporting Person on October 23, 2024.